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ABSTRACT 
Background 
Serotonin is under-researched in Attention-Deficit/Hyperactivity Disorder (ADHD), despite 
accumulating evidence for its involvement in impulsiveness and the disorder. Serotonin furthermore 
modulates temporal discounting (TD), which is typically abnormal in ADHD relative to healthy 
subjects, underpinned by reduced fronto-striato-limbic activation. This study tested whether a single 
acute dose of the selective serotonin reuptake inhibitor (SSRI) fluoxetine upregulates and normalises 
reduced fronto-striato-limbic neurofunctional activation in ADHD during TD.  
Methods 
Twelve boys with ADHD were scanned twice in a placebo-controlled randomised design under either 
fluoxetine (between 8-15mg, titrated to weight) or placebo while performing an individually 
adjusted functional magnetic resonance imaging (fMRI) TD task. Twenty healthy controls were 
scanned once. Brain activation was compared within patients under either drug condition and 
compared to controls to test for normalisation effects.  
Results  
Repeated-measures whole-brain analysis within patients revealed significant upregulation with 
fluoxetine in a large cluster comprising right inferior frontal cortex, insula, premotor cortex and basal 
ganglia, which furthermore correlated trend-wise with TD performance, which was impaired relative 
to controls under placebo, but normalised under fluoxetine. Fluoxetine furthermore downregulated 
default mode areas of posterior cingulate and precuneus. Comparisons between controls and 
patients under either drug condition revealed normalization with fluoxetine in right premotor-
insular-parietal activation, which was reduced in patients under placebo.    
Conclusions 
The findings show that a serotonin agonist upregulates activation in typical ADHD dysfunctional 
areas in right inferior frontal cortex, insula and striatum as well as downregulating default mode 
network regions in the context of impulsivity and TD.  
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INTRODUCTION 
Attention-Deficit/Hyperactivity Disorder (ADHD) is defined as age-inappropriate inattention 
and/or hyperactivity/impulsiveness (APA, 2013). It is one of the most common neurodevelopmental 
disorders with around 5% prevalence worldwide (Polanczyk et al., 2014). ADHD patients have 
deficits in executive functions (EF) such as inhibition, attention and working memory (Willcutt et al., 
2008), underpinned by abnormalities in fronto-striatal, fronto-temporo-parietal and fronto-
cerebellar networks (Hart et al., 2012, Hart et al., 2013, Rubia et al., 2014a). Furthermore, they have 
deficits in timing functions (Noreika  et al., 2013) and in “hot” EF, referring to EF involving motivation 
and affect such as reward-related decision-making (Kerr and Zelazo, 2004), as measured by temporal 
discounting (TD) and gambling tasks (Noreika et al., 2013, Rubia et al., 2009). Nonetheless, there is 
heterogeneity in cognitive impairments, with some patients not showing impairments or only in 
some cognitive domains which are likely underpinned by different pathophysiological pathways 
(Nigg et al., 2005, Sonuga-Barke, 2003, Sonuga-Barke et al., 2010). 
TD tasks require choices between small immediate and larger delayed rewards and measure 
the extent to which a reward is subjectively discounted when delayed in time, i.e., the sensitivity to 
temporal delays measured in units of reward (Rubia et al., 2009). The ability to inhibit immediate 
rewards and wait for larger future rewards depends on well-developed frontal lobe-mediated 
motivation control and temporal foresight and is key for mature decision making. TD matures with 
age (Christakou et al., 2011) and varies between individuals, with steeper TD, i.e., more rapidly 
decaying rates of reward discounting with increasing time (Richards et al., 1999), in more impulsive 
subjects (Noreika et al., 2013, Rubia et al., 2009). In individually-adjusted TD paradigms (Christakou 
et al., 2011, Richards et al., 1997), the immediate reward is adjusted using an algorithm based on 
previous choices for different delays, converging towards the value of the participant’s subjective 
equivalent of the fixed delayed reward (Richards et al., 1999). From this, a typically hyperbolic delay 
discounting function is calculated , the steepness of which indicates the individual TD rate, which is 
associated with impulsivity (Critchfield and Kollins, 2001, Richards et al., 1999). 
ADHD patients are impaired in TD tasks (Noreika et al., 2013), with, however, some negative 
findings, mostly in non-individually-adjusted  task versions (Scheres et al., 2006, Scheres et al., 2010, 
Sonuga‐Barke et al., 1992). FMRI studies of TD in healthy adults implicate ventromedial-fronto-limbic 
networks of reward-based decision-making and dorsolateral and inferior-fronto-insula-striato-
parietal networks of temporal foresight (Christakou et al., 2011, Wesley and Bickel, 2014). Despite 
documented TD deficits in ADHD, few fMRI studies have investigated its neurofunctional correlates.  
ADHD adolescents showed underactivation relative to controls during delayed choices in an adjusted 
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fMRI TD task in inferior frontal cortex (IFC), insula, striatal and cerebellar regions (Rubia et al., 2009) 
and significantly weaker correlations between better TD and activation during delayed choices in IFC, 
superior temporal lobes, insula, supplementary motor area and cerebellum (Chantiluke et al., 
2014d). In adult ADHD, abnormal striato-limbic activation has been observed (Plichta et al., 2009). 
Neurotransmitters such as serotonin (5-HT) are implicated in ADHD (Oades, 2007, 2008), 
potentially via modulation of these neural circuits. Converging evidence across methodologies shows 
that serotonergic systems may be dysfunctional in ADHD (Oades, 2007), with evidence for chemical 
alterations of 5-HT systems, decreased 5-HT platelet levels (Spivak et al., 1999), and increased 
ADHD-related behaviour after 5-HT depletion in ADHD patients (Zepf et al., 2010). Second, there is 
evidence for an association between 5-HT-related polymorphisms and ADHD (Gizer et al., 2009, 
Rommelse et al., 2010) and methylphenidate treatment response (McGough et al., 2009). Also, the 
selective serotonin reuptake inhibitor (SSRI) fluoxetine has been shown to be effective in reducing 
ADHD-related symptoms in children (Barrickman et al., 1991, Quintana et al., 2007) and to improve 
the efficacy of stimulants in human and animal studies (Findling, 1996, Gainetdinov et al., 1999, 
Gammon and Brown, 1993). Furthermore, the concurrent administration of 5-HT and dopamine 
amino-acid precursors can improve ADHD symptoms (Hinz et al., 2011). However, replication is 
needed as these studies are limited by comorbid samples (Quintana et al., 2007) and non-
randomised trials in small samples (Barrickman et al., 1991). Last, in healthy adults, tryptophan 
depletion, which reduces brain 5-HT by up to 60%, downregulates activation in key ADHD deficit 
areas of IFC and basal ganglia (Lamar et al., 2014, Lamar et al., 2009, Rubia et al., 2005), which are 
upregulated with serotonin agonists (Del-Ben et al., 2005). Also, 5-HT has been implicated in reward-
based decision-making in healthy adults (Cools et al., 2011, Robinson et al., 2012, Rogers, 2011), 
where striatal 5-HT levels have been shown to modulate choices of longer, delayed rewards (Doya, 
2008, Schweighofer et al., 2007, Tanaka et al., 2007).  
In conclusion, there is evidence that 5-HT is associated with ADHD, with impulsivity, in 
particular TD performance, and that it modulates IFC-striatal activation, a key ADHD deficit.  Despite 
this, hardly any fMRI studies have tested the effects of serotonin agonists on brain function in ADHD. 
We have previously shown that in ADHD children, the SSRI fluoxetine versus placebo upregulated 
and normalised IFC-striatal and parietal underactivation during inhibition (Chantiluke et al., 2014a, 
Chantiluke et al., 2014c), and enhanced the deactivation in default mode network (DMN) regions 
during working memory (Chantiluke et al., 2014b). 
This study therefore aimed to investigate the effect of a single dose of fluoxetine relative to 
placebo on brain activation in ADHD adolescents during a TD task. Furthermore, to test for potential 
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normalisation effects of fluoxetine on abnormal brain activation in ADHD patients under placebo, we 
also compared brain activation during both drug conditions to that of healthy adolescents. 
Based on previous findings, we hypothesized that ADHD adolescents under placebo would 
show steeper TD rates (Noreika et al., 2013) and reduced IFC-insular-striatal activation during TD 
(Chantiluke et al., 2014d, Plichta et al., 2009, Rubia et al., 2009). Furthermore, based on our fMRI 
studies showing upregulation and normalisation with fluoxetine in task-relevant regions during 
related tasks of cognitive control in ADHD (Chantiluke et al., 2014a, Chantiluke et al., 2014b, 
Chantiluke et al., 2014c), and evidence for 5-HT modulation of IFC-striatal regions in healthy adults 
(Lamar et al., 2009, Rubia et al., 2005), we hypothesized that fluoxetine would upregulate IFC-insula-
striato-parietal activation within patients and normalise regional underactivation relative to controls.  
METHODS 
Participants 
Thirty-two right-handed (Oldfield, 1971) boys with (N=12) and without ADHD (N=20) were 
recruited from local clinics and support groups, aged 11-17 years, with IQ>70 measured by the 
Wechsler Abbreviated Scale of Intelligence-Revised (WASI-R) short form (Wechsler, 1999). ADHD 
boys had a clinical DSM-IV diagnosis of non-comorbid ADHD, inattentive/hyperactive-impulsive 
combined subtype, assessed using the standardized Maudsley diagnostic interview (Goldberg and 
Murray, 2006). Patients scored above clinical threshold for ADHD symptoms on the Strengths and 
Difficulties Questionnaire (SDQ; (Goodman and Scott, 1999)) and the Conner’s Parent Rating Scale-
Revised (CPRS-R; (Conners et al., 1998)). They also scored below clinical threshold for ASD on the 
Social Communication Questionnaire (SCQ; (Rutter et al., 2003)). Nine ADHD boys were on 
psychostimulants but withheld medication for 48 hours prior to scanning.  
Patients were scanned twice in a randomised, double-blind, placebo-controlled design. Due 
to the half-life of fluoxetine (1-3 days) and its metabolite norfluoxetine (5-16 days) (Wong et al., 
1995), scans were conducted 3-4 weeks apart. To ensure the fluoxetine dose had reached peak 
plasma levels (after 5-8 hours (Wong et al., 1995)), patients were scanned 5 hours post-
administration. Liquid fluoxetine was titrated to age and weight: boys 10-13 years and <30kg 
received 8mg, those >30kg received 10mg. Boys 14-17 years and <30kg received 10mg, and those 
>30kg received 15mg. Placebo was equivalent volumes of peppermint water, similar in taste and 
appearance to fluoxetine.  
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Twenty healthy age and handedness-matched control boys were recruited locally by 
advertisement and scanned once. Controls scored below clinical threshold on the SDQ, SCQ and 
CPRS-R and did not have any psychiatric condition.  
Exclusion criteria for all participants were neurological disorders, drug/alcohol dependency 
and MRI contraindications.  
The study was conducted according to the latest version of the Declaration of Helsinki. 
Ethical approval was obtained from the local Research Ethics Committee. Study details were 
explained to both child and guardian, and written informed consent was obtained for all 
participants.  
Temporal Discounting fMRI paradigm 
Prior to the first scan, subjects practiced the 12 min task once in a ‘mock’ scanner. Subjects 
choose by pressing a left or right button between receiving a small amount of money immediately 
(£0-£100) or £100 in one week, month or year. Delay choices (20 trials of each delay length) were 
randomised, but the delayed option was consistently displayed on the right side, and the variable 
immediate choices on the left side of the screen to minimize potential sensorimotor mapping 
effects. Choices were displayed for 4s, followed by a blank screen of at least 8s (inter-trial-interval: 
12s). The amount of immediate reward was adjusted through an algorithm based on previous 
choices which was calculated separately for each of the three delays. This narrows the range of 
values, converging into an indifference point where the immediate reward is considered by the 
subject to be equivalent to the delayed amount for the given delay (Christakou et al., 2011, Rubia et 
al., 2009). This algorithm ensures equal numbers of immediate and delayed choices to be contrasted 
in the fMRI analysis.  
Analysis of Performance Data 
To estimate the steepness of TD for each subject, the indifference value between the 
immediate amount and the delayed £100 for each delay was calculated, equivalent to the subject’s 
subjective value of £100 after each delay, and defined as the midpoint between the lowest 
immediate reward chosen by the subject and the next lowest immediate reward available (i.e. the 
value of the immediate reward offered at which point the subject began to instead consistently 
choose the delayed reward) (Christakou et al., 2011, Rubia et al., 2009).  
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Reward is typically discounted as a hyperbolic decay function depending on amount, delay 
and a free impulsiveness indicator “k”, calculated by fitting a hyperbolic function to the indifference 
values for each delay (see Supplement).  
However, the limitations of the fMRI task adaption, i.e. relatively few trials and only three 
delay points, limit the goodness-of-fit of the data to a non-linear curve function. In addition, the 
distribution of k-values was not normal, skewed by low-frequency and high-value outliers. Thus, TD 
was measured using the area under the curve (AUC) which is more appropriate for investigations 
with quantitative, inferential statistics (Myerson et al., 2001). The normalized subjective values of 
the delayed £100 for each delay were plotted against the normalized delays and AUC of these plots 
were calculated for each participant, using this obtained value as the main dependent variable. AUC 
correlated inversely with k-values (r=-0.898, p<0.001) whereby smaller AUC values denote steeper 
discounting rates, indicating increased choice impulsivity.  
A repeated-measures within-group analysis of variance (ANOVA) was conducted within 
patients with medication condition (placebo, fluoxetine) as within-subjects variable to test for 
medication effects on TD. Two ANOVAs were conducted with group as independent variable and 
area under the curve (AUC) as dependent measure to test for differences in TD performance 
between controls and ADHD patients on either placebo or fluoxetine.  To test for potential main 
effects of drug administration order and of an interaction between order and drug condition, order 
was included as a between-subjects factor in the repeated-measures ANOVA. 
fMRI Image Acquisition 
Gradient-echo echo-planar MR imaging (EPI) data were acquired at King’s College London, 
Institute of Psychiatry’s Centre for Neuroimaging Sciences on a 3T General Electric SIGNA HDx MRI 
scanner (GE Healthcare, UK). For details of scan acquisition, see Supplement. 
fMRI Image Analysis 
Event-related activation data were acquired in randomized trial presentation and analysed 
using the non-parametric XBAM software package developed at the Institute of Psychiatry, King’s 
College London (www.brainmap.co.uk; (Brammer et al., 1997)). The individual and group-level 
analyses methods are described in detail elsewhere (Brammer et al., 1997, Bullmore et al., 1999a, 
Bullmore et al., 2001, Bullmore et al., 1999b, Cubillo et al., 2014b) and in the online Supplementary 
Material.  
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ANCOVA of within-patient medication effects  
To investigate medication effects on brain activation within the ADHD group, a within-group 
repeated-measures analysis of covariance (ANCOVA) with motion as covariate and medication 
condition as within-subjects factor was conducted using randomization-based testing for voxel or 
cluster-wise differences, as described elsewhere (Bullmore et al., 2001, Bullmore et al., 1999b) and 
in the supplementary material. Voxel- and cluster- level statistical thresholds were set so as to 
obtain less than one false positive 3D cluster per map ( p<0.05 was used for voxel and p<0.005 for 
cluster comparisons). The standardised BOLD response values for each participant were extracted 
for each of the significant clusters of the ANCOVA analyses and plotted to determine the direction of 
effects. Repeated-measures ANOVAs on the extracted BOLD response measures were 
conducted within patients to test for potential effects of scan-order and interactions 
between scan order and drug condition. 
 
ANCOVA of between-group effects 
One-way ANCOVAs with group as main factor and motion as covariate were conducted using 
randomization-based testing to test for case-control differences under placebo or fluoxetine 
(Bullmore et al., 2001, Bullmore et al., 1999b). For these comparisons, p<0.05 (voxel-level) and 
p<0.05 (cluster-level) were used. Standardized BOLD responses were then extracted from significant 
clusters for each participant and plotted to determine direction of effects.  
Correlations with behaviour and IQ 
To examine whether clusters which showed group effects in case-control comparisons were 
related to IQ or TD, the BOLD response in these clusters was extracted for each participant and 
Pearson correlations were performed with IQ and AUC within each group (ADHD placebo, ADHD 
fluoxetine, controls).  
RESULTS 
Participant characteristics 
Univariate ANOVA revealed no significant group differences in age, but IQ, which was lower 
in ADHD (Table 1). However, since low IQ is associated with ADHD (Bridgett and Walker, 2006), IQ 
was not covaried as covarying for differences between groups that were not randomly selected 
violates ANCOVA assumptions (Miller and Chapman, 2001). Nonetheless, to assess potential effects 
of IQ on case-control comparisons, BOLD responses were correlated with IQ and analyses were 
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repeated covarying for IQ.  As expected, patients had significantly lower CPRS-R t-scores, SDQ and 
SCQ scores than controls (Table 1). 
Insert Table 1 
 
Performance data 
For repeated-measures ANOVA within-patients, no significant drug effects were found on 
AUC [F(df=1,11)=0.08, p=n.s.], reaction time (RT) [F(df=1,11)=0.08, p=n.s.] or omission errors 
(OM)[F(df=1,7=0.44), p=n.s.] (see Table 1). Case-control ANOVAs showed no differences in RT or OM, 
but controls had larger AUC than patients under placebo [F(df=1,30)=4, p<0.05] but no longer 
differed from patients under fluoxetine [F(df=1,30)=2, p=n.s.], suggesting that fluoxetine normalized 
case-control performance differences (see Table 1).  
Drug administration order had no main effect on the primary behavioral outcome of AUC in 
the ADHD group [F(df=1,10)=.07, p=n.s.] and there was no interaction between scan order and drug 
condition [F(df=1,10)=1.31, p=n.s.]. 
fMRI data 
Motion 
No differences were found for largest head displacement in 3-dimensional space within the 
ADHD group under each drug condition [F(df=2,10)=0.51, p=n.s.].  Also, no group-by-displacement 
interaction was found between controls and ADHD under placebo [F(df=2,29)=2.63, p=n.s.] or 
fluoxetine [F(df=2,29)=2.54, p=n.s]. Nevertheless, to exclude potential effects of non-significant 
motion, motion parameters in 3D-Euclidian space were included as covariates in the fMRI analyses.  
Group brain activation maps for delayed–immediate choices 
For the contrast of delayed minus immediate choices, controls showed activation in 
dorsomedial PFC (dmPFC) and anterior cingulate cortex (ACC), insula, pre- and post-central gyri and 
parieto-occipital and cerebellar regions. ADHD patients on placebo showed activation in ACC, pre- 
and post-central gyrus, posterior cingulate (PCC), and occipito-cerebellar regions, while under 
fluoxetine they showed activation in right dorsolateral and inferior PFC (DLPFC/IFC)/ insula 
extending into basal ganglia (BG), ACC, temporo-parietal and occipital cortices and cerebellum (see 
Supplementary Material and Figure S1). 
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Within-group differences between ADHD patients on placebo versus fluoxetine 
Repeated-measures ANCOVA revealed a significant drug effect in a large cluster comprising 
right IFC, insula, precentral and superior temporal cortices extending into BG, which was enhanced 
under fluoxetine relative to placebo (Figure 1, Table 2A). Post-hoc calculations in SPSS indicated an 
observed power of 89% (partial η2=0.53). Activation in IFC was significantly negatively correlated in 
the placebo group with AUC (r=-0.676, p<0.016). Under Fluoxetine, however, the correlation was at 
a trend-level positive (r=0.563, p=0.057).  
Under placebo relative to fluoxetine, patients had enhanced activation during delayed-
immediate choices in two clusters, one comprising bilateral cerebellar hemispheres and vermis, PCC, 
precuneus and occipital lobe, and the other in left pre- and postcentral gyrus, extending into middle 
frontal gyrus and inferior parietal lobe (IPL) (Figure 1, Table 2B). Furthermore, activation in the 
cerebellum/PCC/precuneus cluster was negatively correlated with the IFC cluster that was 
upregulated under fluoxetine (r=-0.859, p<0.001). 
Drug administration order had no effect on within-group differences in BOLD response [right 
IFC: F(df=1,10)=2.8, p=n.s.; cerebellum/occipital:F(df=1,10)=.40, p=n.s.; left pre/postcentral 
gyrus:F(df=1,10)=.88, p=n.s.], and there was no interaction between drug administration order and 
condition [IFC:F(df=1,10)=0.07, p=n.s.; cerebellum/occipital:F(df=1,10)=0.15, p=n.s.; left 
pre/postcentral gyrus:F(df=1,10)=.75, p=n.s.]. 
Insert Figure 1 + Legend and Table 2 
 
Between-group differences  
Controls versus ADHD patients on placebo 
Between-group ANCOVA showed significantly increased activation in controls relative to 
ADHD under placebo for delayed–immediate choices in 3 right-hemispheric clusters comprising right 
pre- and postcentral gyri, extending into IPL and insula. Patients on placebo showed increased 
activation relative to controls in left anterior cerebellum/occipital lobe (Table 3A, Fig 2A). No 
significant correlations were observed between extracted BOLD response from these clusters and 
IQ. Furthermore, ANCOVA with IQ as covariate showed that all significant clusters remained with the 
exception of right insula. No correlations were observed between AUC and extracted BOLD response 
in any clusters.  
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Controls vs. ADHD patients on fluoxetine 
Controls relative to ADHD patients on fluoxetine showed enhanced activation in left pre- and 
postcentral gyri reaching into IPL. No clusters were increased in ADHD relative to controls (Table 3B, 
Fig 2B). Thus, the right hemispheric clusters which were enhanced in activation in controls relative to 
ADHD under placebo were no longer observed, suggesting that fluoxetine normalized these 
activation differences. No significant correlations were observed between extracted BOLD response 
and IQ.  ANCOVA with IQ as covariate showed that all significant clusters remained. No correlations 
were found between AUC and extracted BOLD response in significant clusters.  
 
Insert Figure 2 + Legend and Table 3 
 
DISCUSSION 
Behaviourally, an acute dose of fluoxetine normalised TD abnormalities in ADHD relative to 
controls.  At the brain level, within patients, fluoxetine relative to placebo significantly upregulated 
activation in a large right-hemispheric IFC-premotor-insular-striatal cluster, which correlated trend-
wise with better TD. Fluoxetine additionally down-regulated activation in presumably default mode 
network activations in PCC/precuneus and in pre and postcentral gyrus/IPL as well as cerebellum. 
Relative to controls, patients on placebo showed underactivation in right insula, pre/postcentral 
gyrus and IPL but enhanced activation in left anterior cerebellum/PCC. Fluoxetine normalized all 
case-control differences, due to upregulation/downregulation of these regions within patients, but 
lead to underactivation in left-hemispheric pre/postcentral gyrus/IPL in ADHD relative to controls, 
due to downregulation of this activation within patients.  
Fluoxetine relative to placebo upregulated a large right-lateralized cluster in ADHD 
comprising IFC, premotor cortex, insula and BG, which was associated trend-wise with better TD. 
This right IFC-insular-striatal network comprises key regions for TD important for integrating external 
information with internal value representations to support goal-directed EF (Christakou et al., 2009, 
Christakou et al., 2013a, Rubia et al., 2009, Wesley and Bickel, 2014, Wittmann et al., 2007). Right 
IFC is a key cognitive control hub region, crucial for inhibiting immediate reward choices as well as 
for inter-temporal bridging and future reward representation (Radua et al., 2014, Wiener et al., 
2010). The BG are linked to a reward-valuation network that mediates reinforcement learning, 
reward-processing and inter-temporal bridging (Koch et al., 2009, Peters and Büchel, 2011, 
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Wittmann et al., 2007) while the insula plays a role in future reward-value representation as well as 
timing functions including temporal foresight (Carter et al., 2010, Radua et al., 2014, Wesley and 
Bickel, 2014, Wiener et al., 2010). In particular right hemispheric IFC, insula and BG have been shown 
to be consistently hypoactivated in ADHD in meta-analyses of EF tasks (Cortese et al., 2012, Hart et 
al., 2013), including TD (Chantiluke et al., 2014d, Rubia et al., 2009). Right IFC underactivation has 
furthermore been shown to be disorder-specific relative to other childhood disorders such as 
conduct and obsessive-compulsive disorder (Norman et al., 2015, Rubia, 2011, Rubia et al., 2014a). 
In this study, we only observed underactivation in ADHD relative to healthy adolescents in insula and 
premotor regions, rather than in IFC and basal ganglia, presumably due to low power.  
Given that our recent meta-analysis findings of a consistent upregulation with stimulants of 
right IFC, insula and BG activation in ADHD (Rubia et al., 2014b), the findings suggest that serotonin 
agonists may have comparable upregulatory effects to stimulants. In fact, the upregulated region in 
VLPFC reaching into anterior insula, putamen and superior temporal lobe is in a very similar location 
to the cluster observed in our meta-analysis of methylphenidate effects on ADHD brain function 
(Talairach coordinates: 42,20,-12), with a sizeable effect size of 1 relative to the meta-analytic effect 
size of 1.5 (Rubia et al., 2014b). Furthermore, it is strikingly similar to the upregulated IFC location in 
our fMRI studies of methylphenidate effects on inhibition and timing, with effect sizes of .7 and .2 
respectively (Cubillo et al., 2014b, Rubia et al., 2014b, Smith et al., 2013). The finding of right IFC-
striatal upregulation together with normalisation of behavioural TD deficits extends previous 
evidence for modulation of behavioural TD rates with 5-HT (Schweighofer et al., 2008, Schweighofer 
et al., 2007) and of IFC-striatal activation with 5-HT modulators such as tryptophan depletion and 
SSRIs in healthy adults (Del-Ben et al., 2005, Lamar et al., 2009, Rubia et al., 2005) to the ADHD 
population.  It also extends our previous findings in ADHD that fluoxetine enhances and normalises 
frontal activation during other impulsiveness-related functions such as IFC-striatal regions during 
inhibition (Chantiluke et al., 2014c) and DLPFC during working memory (Chantiluke et al., 2014b). 
The findings of right IFC modulation suggest that indoleamine agonists have similar effects to 
catecholamine agonists on ADHD brain function, given that not only methylphenidate but also 
atomoxetine  upregulated right IFC activation during inhibition and timing (Cubillo et al., 2014a, 
Cubillo et al., 2014b, Smith et al., 2013). 
The fact that fluoxetine normalised both, underactivation in right pre/postcentral gyri, insula 
and IPL and behavioural TD deficits in ADHD is in line with the role of lateral fronto-insular-striato-
parietal circuitry in intertemporal choice (Bickel et al., 2009, McClure et al., 2004, Xu et al., 2009) 
and for the modulation of these regions by 5-HT (Cools et al., 2011, Long et al., 2009, Robinson et al., 
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2012, Rogers, 2011). Apart from fronto-insular-striatal regions, IPL are also consistently 
underactivated in ADHD during EF (Cortese et al., 2012, Hart et al., 2012, Hart et al., 2013). We have 
found left IPL underactivation to be normalised in ADHD with fluoxetine during inhibition (Chantiluke 
et al., 2014c). The upregulation and normalization with fluoxetine of insula, pre/postcentral and IPL 
deficits in ADHD thus provides promising novel evidence for modulatory effects of serotonin 
agonists on typically dysfunctional fronto-insular-parietal systems in ADHD.  
The downregulation of PCC/precuneus under fluoxetine versus placebo likely reflects 
deactivation of the DMN, comprised of ACC, precuneus and PCC, thought to represent mind-
wandering, and which is typically anti-correlated with task-positive regions as it needs to be 
switched off during cognitive effort (Northoff et al., 2010). This is reinforced by the negative 
correlation under placebo of this cluster with the IFC activation. There is accumulating evidence that 
the DMN is insufficiently deactivated and anticorrelated with task-positive activation in ADHD 
(Christakou et al., 2013b), leading to enhanced mind-wandering, poor attention, EF and timing 
functions. We have found a similar effect of fluoxetine enhancing the deactivation of PCC during 
working memory in ADHD patients (Chantiluke et al., 2014b), which we also observed with 
methylphenidate and atomoxetine (Cubillo et al., 2014a). The finding suggests that fluoxetine, like 
catecholamine agonists (Rubia et al., 2014b), can strengthen the weak deactivation of the DMN in 
ADHD, presumably improving mind wandering. Given that the key functional deficits in ADHD are 
both reduced activation in key fronto-striato-parietal networks mediating EF as well as a reduced 
deactivation of the DMN (Rubia et al., 2014a), the findings suggest that a 5-HT agonist positively 
modulates both “task-positive” as well as “task-negative” activation deficits of not switching off the 
DMN. 
5-HT is relatively ubiquitous in the brain. However, 5-HT modulates specifically ADHD-
relevant impulsivity-related functions mediated by ventrolateral-prefrontal regions which are 
dependent on 5-HT input such as inhibitory control and reward-related decision making (Dalley and 
Roiser, 2012). The upregulation with a 5-HT agonist of key right-hemispheric IFC-striatal activation 
that is typically abnormal in ADHD suggests that abnormal 5-HT may be underlying abnormal 
activation in these networks and not just catecholamine systems, in line with accumulating evidence 
of a role of 5-HT in ADHD (Barrickman et al., 1991, Gizer et al., 2009, Hinz et al., 2011, McGough et 
al., 2009, Oades, 2008, Quintana et al., 2007, Rommelse et al., 2010, Spivak et al., 1999, Zepf et al., 
2010). However, it cannot be ruled out that fluoxetine had no indirect effects on other 
neurotransmitter systems which are known to be influenced by 5-HT such as dopamine, 
acetylcholine and other monoamines (Bymaster et al., 2002, Mongeau et al., 1997, Oades, 2008). All 
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3 main monoamine systems are likely to interact in a concerted manner to mediate impulsiveness-
relevant functions (Dalley and Roiser, 2012).  
The strength of this study is a carefully selected non-comorbid ADHD group. Limitations are 
a relatively small patient sample size and the fact that for ethical and financial considerations, the 
control group was scanned only once while patients were scanned twice. However, the 
randomisation accounted for potential training effects, and order did not affect the results. The 
significantly lower IQ in the ADHD group, typical for the population,  is a limitation, in particular 
because IQ impacts upon decision making (Toplak et al., 2010).However, covariance and correlation 
findings did not suggest that IQ confounded group differences. Finally, long-term stimulant use 
affects brain function and structure, so deficit findings may have been mitigated by the majority of 
patients taking stimulant medication (Hart et al., 2012, Rubia et al., 2014a). 
Conclusions 
               A single fluoxetine dose in ADHD upregulated activation in key right IFC-premotor-insular-
striatal circuitry that mediates TD and which correlated trend-wise with better TD, and enhanced the 
deactivation of posterior DMN regions. Moreover, fluoxetine, via upregulation of these right 
hemispheric regions, normalized underactivation in ADHD under placebo relative to controls in right 
premotor-insular-parietal areas and behavioural TD abnormalities.  The findings show for the first 
time that a serotonin agonist can modulate right IFC -insular-striato-parietal neural mechanisms 
underlying poor temporal foresight in ADHD. While the study aim was to clarify the mechanism of 
action of an acute dose of fluoxetine, which has the advantage of revealing true drug effects not 
confounded by indirect symptom improvements after chronic administration, future studies need to 
assess longer-term effects, as clinical behavioural changes are typically observed after weeks of 
administration. Longer-term SSRI administration has been shown to lead to downregulation of 5-
HT1a receptors and serotonin transporters (Lesch et al., 1991) and may well have different effects 
on brain function than acute doses, which are clinically more informative. 
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Table 1. Participant characteristics 
Abbreviations: SD=standard deviations; DF=degrees of freedom; Plac=placebo; Fluox=fluoxetine; 
RT=reaction time; ms=milliseconds; OM=omissions 
* CPRS-R total T-score could not be obtained for 4 control participants 
† SCQ scores could not be obtained from 3 control participants 
‡ SDQ scores could not be obtained from 2 control participants 
   
Variables 
Controls (N=20) 
Mean (SD) 
ADHD (N=12) 
Mean (SD) 
F test 
(DF) 
p value 
Demographic Data     
   Age (years) 15.29 (1.78) 14.86 (1.71) 0.43 (1,30) 0.52 
   Handedness 88.4 (16.37) 92.92 (11.48) 0.70 (1,30) 0.41 
   IQ 118.9 (11.91) 94.5 (7.35) 40.71 (1,30) < 0.001 
   CPRS-R total T-score *  48.63 (8.82) 82.83 (7.79) 113.79 (1,26) < 0.001 
   SCQ total score † 2.24 (2.51) 6.58 (3.29) 16.32 (1,27) < 0.001 
   SDQ total score ‡ 4.89 (3.69) 20.75 (4.31) 116.32 (1,28) < 0.001 
Performance Data     Plac/Fluox   
   AUC 0.557 (0.13) 0.440 (0.20)/0.458 (0.23) - - 
   RT (ms) 2141 (591.47) 2354 (578.6)/2306 (381.5) - - 
   OM 0.75 (1.83) 1.92 (2.4)/1.58 (2.0) - - 
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Table 2. Within-patient comparisons of activation differences for delayed-immediate choices 
Brain regions of activation 
difference 
Brodmann Area (BA) 
MNI coordinates 
(x,y,z) 
Voxels 
Cluster p 
value 
Partial 
eta2 
(A) ADHD Fluoxetine > ADHD Placebo  
R IFC/DLPFC/insula/precentral 
gyrus/STL/putamen/caudate/ 
globus pallidus 
47/10/46/45/6/22 52,0,-20 107 0.003 0.53 
(B) ADHD Placebo > ADHD Fluoxetine  
L + R lateral cerebellum & 
vermis/occipital lobe/ 
PCC/precuneus 
30/31/23/19/18 -11,-75,-12 384 0.0002 0.38 
L postcentral/precentral 
gyri/IPL/middle frontal gyrus  
2/3/1/6/40/5 -30,-22,48 116 0.0007 0.38 
Abbreviations: R=right; L=left; IFC=inferior frontal cortex; DLPFC=dorsolateral prefrontal cortex; STL=superior 
temporal lobe; PCC=posterior cingulate cortex; IPL=inferior parietal lobe. Partial eta2 refers to the effect size 
of the differences in activation between groups. 
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Table 3. Case-control comparisons of activation differences for delayed-immediate choices 
Subject contrast 
Brain regions of activation 
difference 
Brodmann Area 
(BA) 
MNI 
coordinates 
(x,y,z) 
Voxels 
Cluster p 
value 
Partial 
eta2 
(A) CONTROLS versus ADHD PLACEBO  
C > ADHD  R pre/postcentral gyrus/insula           6/4/3/2 
 
56,-5,5 14 0.04 0.10 
 R precentral/postcentral gyrus 6/4/3/2/1/40 41,-11,37 25 0.04 0.19 
 R postcentral gyrus/IPL 4/1/2/40 -34,-22,45 14 0.04 0.24 
 L postcentral gyrus/IPL 2/3/40 -34,-22,45 4 0.03 0.08 
ADHD > C 
L cerebellum 
(anterior)/occipital lobe/PCC 
19/30 -14,-71,-12 16 0.02 0.12 
(B) CONTROLS versus ADHD FLUOXETINE  
C > ADHD  
L precentral/postcentral 
gyri/IPL 
6/4/3/2/1/40 -34,-22,45 77 0.001 0.27 
ADHD > C  No observed clusters - - - - - 
Abbreviations: R=right; L=left; IPL=inferior parietal lobe. Partial eta2 refers to the effect size of differences in 
activation between groups. 
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Figure Legends 
Fig. 1. Within-patient comparisons. Axial sections show medication effects within the ADHD group. 
RED=fluoxetine > placebo, BLUE=placebo > fluoxetine. Also shown are the statistical measures of the 
blood oxygen level-dependent (BOLD) response for each of the brain regions that showed a 
significant effect of medication within patients. R=right, L=left; IFC=inferior frontal cortex; 
STL=superior temporal lobe; PCC=posterior cingulate cortex; IPL=inferior parietal lobe; MFG=middle 
frontal gyrus. Talairach z-coordinates are indicated for slice distance (in mm) from the 
intercommissural line. The right side of the image corresponds to the right side of the brain. 
 
Fig. 2. Case-control comparisons. Axial sections show the between-group ANCOVA findings between 
controls and patients under (A) placebo and (B) fluoxetine. RED=controls > ADHD, BLUE=ADHD > 
controls. Also shown are the statistical measures of the blood oxygen level-dependent (BOLD) 
response for each of the brain regions that showed a significant group effect. R=right, L=left, 
IPL=inferior parietal lobe, CB=cerebellum. Talairach z-coordinates are indicated for slice distance (in 
mm) from the intercommissural line. The right side of the image corresponds to the right side of the 
brain. 
 
 
